Risk factor
Very poor trading liquidity
Profitability factor
Favourable analyst view
About
Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The company's portfolio features the Tetanus Quick Stick, an essential emergency diagnostic for rapidly determining a patient's tetanus vaccination status. It also distributes cell culture media, molecular biology reagents, and proprietary antibody solutions. Proprietary developments from Eurobio Scientific encompass the BJI InoPlex, a multiplex serological test for diagnosing prosthetic joint infections, and the EBX-044 PCR test, utilized for identifying SARS-CoV-2 variants. Its licensed offerings include AlloMap, a gene-expression profiling blood test designed for the ongoing surveillance of heart transplant recipients. The firm, initially named Diaxonhit, changed its corporate identity to Eurobio Scientific S.A. in June 2018. Founded in 1997, the company is headquartered in Les Ulis, France.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair
Target Price
The average target price of ALERS.PA is 30.0 and suggests 42.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to